Repercusión de vortioxetina sobre la función sexual frente a otros antidepresivos(Pag.-e 101997)

  1. F. Sánchez-Sánchez 1
  2. B. Ponce-Buj 2
  3. A.L. Montejo-González 3
  4. Y. Sipán-Sarrión 1
  5. A. Gimeno-Marqués 4
  6. A. Merino-Gámez 5
  1. 1 Centro de Salud Xàtiva, Xàtiva, Valencia, España
  2. 2 Centro de Salud Alaquàs, Alaquàs, Valencia, España
  3. 3 Clínico Universitario de Salamanca, Salamanca, España
  4. 4 Centro de Salud L’Alcúdia, L’Alcúdia, Valencia, España
  5. 5 Centro de Salud Rafelbunyol, Rafelbunyol, Valencia, España
Mostrar afiliacións +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Ano de publicación: 2023

Número: 7

Páxinas: 2-2

Tipo: Artigo

DOI: 10.1016/J.SEMERG.2023.101997 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Semergen: revista española de medicina de familia

Obxectivos de Desenvolvemento Sustentable

Resumo

Objective To analyze the impact of the antidepressant vortioxetine on sexual function, compared to selective serotonin reuptake inhibitors (SSRIs) and mixed selective serotonin and norepinephrine reuptake inhibitors (IRSN or Dual) in patients with depression. Material and methods Analytical, observational, longitudinal and prospective study, which included men and women over 18 years of age, with depressive disorder and sexual activity with a partner, separating them into two groups: (i) study, starting treatment with vortioxetine; (2) control, maintaining treatment with SSRIs or Duals. Three visits were made: inclusion, follow-up at 4 weeks and final 3 months from inclusion. The total follow-up period was 3 months. Results A total of 87 patients were included (mean age 46.85 years). At the end of the study, significant differences (SD) were found in the mean value of the sum of the scores of the evaluative domains of the sexual response of the Women's Sexual Function Questionnaire (FSM-2) between the study group and the control (22.42 ± 4.39 and 16.13 ± 7.76, respectively), with a lower risk of sexual dysfunction in women treated with vortioxetine. Also, lower risk of sexual dysfunction in these same women in the domains of desire, lubrication, orgasm, sexual frequency and sexual satisfaction. These differences were not found when assessing male sexual function. Conclusions Women treated with vortioxetine presented better sexual function than those treated with SSRIs or Duals and a lower risk of sexual dysfunction.

Referencias bibliográficas

  • U. Reichenpfader, G. Gartlehner, L.C. Morgan, A. Greenblatt, B. Nussbaumer, R.A. Hansen, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis Drug Saf., 37 (2014), pp. 19-31, 10.1007/s40264-013-0129-4 View PDF Your institution provides access to this article. View in ScopusGoogle Scholar
  • V.S. Williams, H.M. Edin, S.L. Hogue, S.E. Fehnel, D.S. Baldwin Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: Replication in a cross-sectional patient survey J Psychopharmacol., 24 (2010), pp. 489-496, 10.1177/0269881109102779 View PDF Your institution provides access to this article. View in ScopusGoogle Scholar
  • A.L. Montejo, L. Montejo, D.S. Baldwin The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management World Psychiatry., 17 (2018), pp. 3-11, 10.1002/wps.20509 View PDF This article is free to access. View in ScopusGoogle Scholar
  • K.U. Lee, Y.M. Lee, J.M. Nam, H.K. Lee, Y.S. Kweon, C.T. Lee, et al. Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting Psychiatry Investig., 7 (2010), pp. 55-59, 10.4306/pi.2010.7.1.55 View article View in ScopusGoogle Scholar
  • A.L. Montejo, J. Calama, F. Rico-Villademoros, L. Montejo, N. González-García, J. Pérez, SALSEX Working Study Group A real-world study on antidepressant-associated sexual dysfunction in 2144 outpatients: The SALSEX I study Arch Sex Behav., 48 (2019), pp. 923-933, 10.1007/s10508-018-1365-6 View PDF Your institution provides access to this article. View in ScopusGoogle Scholar
  • A.L. Montejo, J.F.W. Deakin, R. Gaillard, C. Harmer, F. Meyniel, A. Jabourian, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale J Psychopharmacol., 29 (2015), pp. 1119-1128, 10.1177/0269881115599385 View PDF Your institution provides access to this article. View in ScopusGoogle Scholar
  • C. Sanchez, K.E. Asin, F. Artigas Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data Pharmacol Ther., 145 (2015), pp. 43-57, 10.1016/j.pharmthera.2014.07.001 View PDFView articleView in ScopusGoogle Scholar
  • E. Salagre, I. Grande, B. Solé, J. Sanchez-Moreno, E. Vieta Vortioxetine: A new alternative for the treatment of major depressive disorder Rev Psiquiatr Salud Ment (Engl Ed)., 11 (2018), pp. 48-59, 10.1016/j.rpsm.2017.06.006 View PDFView articleView in ScopusGoogle Scholar
  • S.H. Lee, S.W. Jeon, C. Shin, C.U. Pae, A.A. Patkar, P.S. Masand, et al. Acute efficacy and safety of escitalopram versus desvenlafaxine and vortioxetine in the treatment of depression with cognitive complaint: A rater-blinded randomized comparative study Psychiatry Investig., 19 (2022), pp. 268-280, 10.30773/pi.2021.0368 View article View in ScopusGoogle Scholar
  • M. Koesters, G. Ostuzzi, G. Guaiana, J. Breilmann, C. Barbui Vortioxetine for depression in adults Cochrane Database of Systematic Reviews (2017), 10.1002/14651858 Art. No.: CD011520 [consultado 12 Mar 2023], CD011520.pub2 View PDF Your institution provides access to this article. Google Scholar
  • P.L. Jacobsen, G.G. Nomikos, W. Zhong, A.J. Cutler, J. Affinito, A. Clayton Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: A comparison between vortioxetine and escitalopram CNS Spectr., 25 (2020), pp. 50-63, 10.1017/S1092852919000750 View articleView in ScopusGoogle Scholar
  • A. Lobo, L. Chamorro, A. Luque, R. dal-Ré, X. Badia, E. Baró, Grupo de Validación en Español de Escalas Psicométricas (GVEEP) Validación de las versiones en español de la Montgomery-Asberg Depression Rating Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedad [Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales] Med Clin (Barc)., 118 (2002), pp. 493-499, 10.1016/s0025-7753(02)72429-9 View PDFView articleView in ScopusGoogle Scholar
  • J. Busner, S.D. Targum The clinical global impressions scale: Applying a research tool in clinical practice Psychiatry (Edgmont)., 4 (2007), pp. 28-37 PMID: 20526405; PMCID: PMC2880930 Google Scholar
  • F. Sánchez-Sánchez, C. Ferrer-Casanova, B. Ponce-Buj, Y. Sipán-Sarrión, A.R. Jurado-López, C. San Martin-Blanco, et al. Diseño y validación del Cuestionario de Función Sexual del Hombre, FSH Semergen., 46 (2020), pp. 441-447, 10.1016/j.semerg.2019.12.005 View PDFView articleView in ScopusGoogle Scholar
  • F. Sánchez-Sánchez, C. Ferrer-Casanova, B. Ponce-Buj, Y. Sipán-Sarrión, A.R. Jurado-López, C. San Martin-Blanco, et al. Diseño y validación de la segunda edición del Cuestionario de Función Sexual de la Mujer, FSM-2 Semergen., 46 (2020), pp. 324-330, 10.1016/j.semerg.2020.01.004 View PDFView articleView in ScopusGoogle Scholar
  • A. Cipriani, T.A. Furukawa, G. Salanti, A. Chaimani, L.Z. Atkinson, Y. Ogawa, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis Lancet., 391 (2018), pp. 1357-1366, 10.1016/S0140-6736(17)32802-7 View PDFView articleView in ScopusGoogle Scholar
  • C.B. Montano, W.C. Jackson, D. Vanacore, R.H. Weisler Practical advice for primary care clinicians on the safe and effective use of vortioxetine for patients with Major Depressive Disorder (MDD) Neuropsychiatr Dis Treat., 18 (2022), pp. 867-879, 10.2147/NDT.S337703 View PDF This article is free to access. Google Scholar
  • M.A. Reed Female sexual dysfunction Clin Plast Surg., 49 (2022), pp. 495-504, 10.1016/j.cps.2022.06.009 View PDFView articleView in ScopusGoogle Scholar
  • R. Basson, T. Gilks Women's sexual dysfunction associated with psychiatric disorders and their treatment Women's Health., 14 (2018), 10.1177/1745506518762664 View PDF This article is free to access. Google Scholar
  • S.A. Kingsberg Identifying HSDD in the family medicine setting J Fam Pract., 58 (7 Suppl Hypoactive) (2009), pp. S22-S25 PMID: 19825315 View in ScopusGoogle Scholar
  • A.L. Montejo, G. Llorca, J.A. Izquierdo, F. Rico-Villademoros, Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction J Clin Psychiatry., 62 (Suppl 3) (2001), pp. 10-21 PMID: 11229449 View in Scopus
  • A.M. Bakr, A.A. El-Sakka, A.I. El-Sakka Pharmaceutical management of sexual dysfunction in men on antidepressant therapy Expert Opin Pharmacother., 23 (2022), pp. 1051-1063, 10.1080/14656566.2022.2064218 View article View in ScopusGoogle Scholar
  • J. Rothmore Antidepressant-induced sexual dysfunction Med J Aust., 212 (2020), pp. 329-334, 10.5694/mja2.50522 View PDF Your institution provides access to this article. View in ScopusGoogle Scholar
  • T.E. Schwasinger-Schmidt, M. Macaluso Other Antidepressants Handb Exp Pharmacol., 250 (2019), pp. 325-355, 10.1007/164_2018_167 View article View in ScopusGoogle Scholar
  • P. Jacobsen, W. Zhong, G. Nomikos, A. Clayton Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults: A randomized, controlled trial J Sex Med., 16 (2019), pp. 1638-1649, 10.1016/j.jsxm.2019.06.018 View PDFView articleView in ScopusGoogle Scholar
Fonte de datos: Dialnet